Resistance to thyroid hormone (RTH) is a condition caused by a mutation in the thyroid hormone receptor gene. It is rarely reported in individuals with no family history of RTH or in premature infants, and its clinical presentation varies. In our case, a prema ture infant with no family history of thyroid diseases had a thyroid sti mulating hormone level of 85.0 μIU/mL and free thyroxine level of 1.64 ng/dL on a thyroid function test. The patient also presented with clinical signs of hypothyroidism, including difficulties in feeding and weight gain. The patient was treated with levothy roxine; however, only free thyroxine and triiodothyronine levels increased without a decrease in thyroidstimulating hormone levels. Taken together with thyroid gland hypertrophy observed on a previous ultrasound examination, RTH was suspected and the diagnosis was eventually made based on a genetic test. A de novo mutation in the thyroid hormone receptor β gene in the infant was found that has not been previously reported. Other symptoms included tachycardia and pulmonary hypertension, but gradual improve ment in the symptoms was observed after liothyronine administra tion. This report describes a case involving a premature infant with RTH and a de novo mutation, with no family history of thyroid disease.
INTODUCTION
Resistance to thyroid hormone (RTH) is a genetic disorder caused by a thyroid hormone receptor (THR) gene mutation, which results in a reduced response of THRs located on tissues 13) . RTH mostly occurs because of a mutation in thyroid hormone receptor beta (THRB); however, RTH caused by a mutation in the thyroid hormone receptor α gene (THRA) was also reported recently 4) . , and Jae Woo Lim RTH is characterized by elevated free thyroxine (FT4) and triiodothyronine (T3) levels and normal or elevated thyroid stimulating hormone (TSH) levels; however, TSH levels decrease when a supraphysiologic dose of thyroid hormone is admini stered 1) . The clinical features of RTH are determined by the se verity of hormone resistance. In most pediatric patients with RTH, symptoms of goiter, thyrotoxicosis, developmental disor ders, and growth failure accompanied by delayed bone age are observed 1, 2, 5, 6) . RTH is typically inherited in an autosomal dominant pattern and thus is often identified in advance by taking the family history 7) . RTH affects approximately one in 40,000 newborns and is rarely diagnosed in premature infants 8) . Here, we report a case involving a premature infant with RTH and a de novo mutation, with no family history of thyroid disease, together with tachy cardia and pulmonary hypertension findings.
Thyroid Hormone Resistance in a Preterm

CASE REPORT
The female infant in our case was delivered naturally at a gestational age of 36 weeks and 1 day. Her mother was 42 years old and had an obstetric history of gravida 3, para 3, living 3, death 0, abortion 0. Specific family history of diseases including thyroid disease were absent. The mother gave birth after uncontrollable early pain and presence of oligohydramnios (amniotic fluid index of 3 cm) on a prenatal examination. The delivery was performed rapidly. The infant had 1 and 5minute Apgar scores of 4 and 7 points, respectively. Immediately after birth, the infant exhibited signs of cyanosis, meconium staining throughout the entire body, and poor activity. Cyanosis and poor activity were ameliorated after ambubagging. The infant weighed 2,160 g (3rd to 10th percentile) and was 43 cm in height (3rd to 10th percentile) with a head circumference of 31 cm (10th to 25th percentile).
Her blood pressure was 82/51 mm Hg; heart rate, 165 beats per minute; respiratory rate, 67 beats per minute; body temperature, (Table 1) . Furthermore, goiter size decreased and heart rate returned to baseline levels. Thereafter, the patient was followed up on an outpatient basis and discharged. After discharge, the infant's parents underwent thyroid function and genetic testing, which revealed normal results.
The outpatient thyroid function test performed on day 104 after birth revealed that TSH (12.77 μIU/mL), FT4 (6.68 ng/ dL), and T3 (649.34 ng/dL) levels were not controlled. Thus, the infant remained on liothyronine and is still being followed up.
Echocardiography performed on day 115 after birth showed 
DISCUSSION
This case is significant because RTH was diagnosed in a pre mature infant without a family history of thyroid disease. RTH is typically reported in children or adults and is rarely observed in neonates or premature infants 9, 10) . Additionally, RTH often occurs in individuals with a family history of the same disorder or other thyroid diseases 11, 12) . When the mother is confirmed to have the disease, a fetal DNA test may be performed to check for morbidity in the fetus 13, 14) . In our case, the infant was initially determined to have hypothyroidism with no family history of RTH, and a thyroid function test revealed an excessively high TSH level and normal FT4 level. RTH was suspected based on followup observations of subsequent thyroid function tests and the infant was eventually diagnosed with RTH based on genetic testing results. RTH is often misdiagnosed as hypothyroidism, hyperthyroidism, or thyroid cancer until a definitive diagnosis is established, resulting in ineffective drug or surgical treatment 15) . THRA and THRB encode THRs. Thyroid hormone receptors α1 (TRα1) are typically located in the heart, bones, and brain; TRβ1 are located in the brain, liver, kidney, and thyroid gland;
and TRβ2 are located in the pituitary, hypothalamus, retina, and inner ear 1, 2) . RTH is mostly associated with THRB mutations and clinical features of hypothyroidism may appear because of the resistance of peripheral tissues to thyroid hormone 1) . In our case wherein a heterozygous mutation in THRB was confirmed, the infant presented with symptoms of hypothyroidism, includ ing intrauterine growth retardation and difficulties in feeding and weight gain. Furthermore, symptoms of tachycardia and irrit ability were also observed, which are symptoms of thyrotoxicosis appearing from normal TRα stimulated by thyroid hormone.
Because TRβ is found throughout the cochlea and plays an im portant role in hearing development, the sensorineural hearing loss in our case may be associated with this condition 16) . More over, the symptoms of dyspnea and pulmonary hyperten sion in the infant shortly after birth and impaired thyroid func tion may be associated.
In a previously reported case, unlike in our case, RTH was iden tified in the mother. Abnormal thyroid hormone levels were found in the fetus, and the subsequent birth resulted in the infant being born with multiple organ failure and respiratory distress syndrome 13) . Additionally, hyperthyroidism increases cate chola mine sensitivity and an overactive sympathetic nervous system increases pulmonary vasoconstriction and metabolism of in trinsic pul monary vasodilators, leading to pulmonary hyperten sion 17) .
Most cases of RTH remain untreated because they tend to be asymptomatic due to increased thyroid hormone secretion, which provides adequate compensation 18) . However, when a pa tient has goiter and presents with various symptoms associat ed with RTH, as in the infant in our case, it is necessary to carefully monitor and administer thyroid hormone when re quired. Liothy ronine is a synthetic form of T3 and metaboli cally active thyroid hormone that suppresses TSH. Liothyronine can be used to treat peripheral tissues in which the transition from T4 to T3 is impaired. Recent reports indicated that administering a supraphysiologic dose of T3 every alternate day effectively reduces goiter without inducing thyrotoxicosis 19) . The infant in our case was also administered liothyronine every alternate day, after which hypertrophy of the thyroid glands disappeared and tachycardia improved 10 days after starting administration. However, because thyroid hormone 
